The Journal of Urology
Volume 177, Issue 1 , Pages 25-30 , January 2007

Role of α-Blockers in Type III Prostatitis: A Systematic Review of the Literature

  • Vibhash C. Mishra

      Affiliations

    • Wexham Park Hospital, London, United Kingdom
    • Corresponding Author InformationCorrespondence: 5 Lincolnshire Gardens, Warfield, Bracknell RG42 3XB, United Kingdom
    • ,
  • John Browne

      Affiliations

    • Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
    • ,
  • Mark Emberton

      Affiliations

    • Institute of Urology and Nephrology, University College London, London, United Kingdom

Received 28 December 2005

References 

  1. Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DJ, Jacobsen SJ. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology. 1998;51:578
  2. McNaughton-Collins M, Meigs JB, Barry MJ, Walker CE, Giovannucci E, Kawachi I. Prevalence and correlates of prostatitis in Health Professionals Follow-up Study Cohort. J Urol. 2002;167:1363
  3. McNaughton-Collins M, Stafford RS, O’Leary MP, Barry MJ. How common is prostatitis? (A national survey of physician visits). J Urol. 1998;159:1224
  4. Nickel JC, Nigro M, Valiquette L, Anderson P, Patrick A, Mahoney J, et al. Diagnosis and treatment of prostatitis in Canada. Urology. 1998;52:797
  5. Lobel B, Rodriguez A. Chronic prostatitis: what we know, what we do not know, and what we should do!. World J Urol. 2003;21:57
  6. Wenninger K, Heiman JR, Rithman I, Berghuis JP, Berger BE. Sickness impact on chronic nonbacterial prostatitis and its correlates. J Urol. 1996;155:965
  7. Krieger JN, Nyberg L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236
  8. Litwin MS, McNaughton-Collins M, Fowler FJ, Nickel JC, Calhoun EA, Pontari MA, et al. The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. J Urol. 1999;162:369
  9. Propert KJ, Alexander RB, Nickel JC, Kusek JW, Litwin MS, Landis JR, et al. Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2002;59:870
  10. Caropreso D, Moon TD. α-Blockers: an effective treatment for prostatitis?. Curr Urol Rep. 2000;1:148
  11. Nickel JC. The use of α1-adrenoreceptor antagonists in lower urinary tract symptoms: Beyond benign prostatic hyperplasia. Urology. 2003;62(suppl):34
  12. Schaeffer AJ. Editorial: emerging concepts in the management of prostatitis/chronic pelvic pain syndrome. J Urol. 2003;169:597
  13. Schaeffer AJ. Etiology and management of chronic pelvic pain syndrome in men. Urology. 2004;63(suppl):75
  14. Schaeffer AJ, Weidner W, Barbalias GA, Botto H, Johansen TEB, Hochreiter WW, et al. Summary Consensus Statement: diagnosis and management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2003;2(suppl):1
  15. Anderson RU. Management of chronic prostatitis-chronic pelvic pain syndrome. Urol Clin North Am. 2002;29:235
  16. Barbalias GA. Why alpha-blockers in prostatitis?. Eur Urol. 2003;2(suppl):27
  17. Malloy BJ, Price DT, Price RR, Bienstock AM, Dole MK, Funk BL, et al. Alpha 1-adrenergic receptor subtypes in human detrusor. J Urol. 1998;160:937
  18. Ishizuka O, Persson K, Mattiasson A. Micturition in conscious rats with and without bladder outlet obstruction: role of spinal α1-adrenoceptors. Br J Pharmacol. 1996;117:962
  19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1
  20. Mehik A, Alas P, Nickel J, Sarpola A, Helstrom P. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology. 2003;62:425
  21. Cheah P, Liong M, Yuen K, Teh C, Khor T, Yang J, et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized placebo controlled trial. J Urol. 2003;169:592
  22. Nickel J, Narayan P, McKay J, Doyle C. Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol. 2004;171:1594
  23. Alexander RB, Propert KJ, Schaeffer AJ, Landis JR, Nickel JC, O’Leary MP, et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind trial. Ann Intern Med. 2004;141:581
  24. Sivkov A, Oshepkov V, Egorov A, Pataki K. Terazosin in patients with chronic prostatitis. BJU Int. 2004;94(suppl):5
  25. Batstone RD, Lynch J, Dobble A. A randomized-placebo controlled pilot study of tamsulosin, naproxen, and combination in category IIIA/IIIB chronic prostatitis/chronic pelvic pain syndrome. J Urol. 2005;173(suppl):30
  26. Lacquaniti S, Destito A, Servello C, Candidi MO, Weir JM, Brisinda G, et al. Terazosine and tamsulosin in nonbacterial prostatitis: a randomized placebo-controlled study. Arch Ital Urol Androl. 1999;71:283
  27. Gul O, Eroglu M, Ozok U. Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Int Urol Nephrol. 2001;32:433
  28. Evliyaoglu Y, Burgut R. Lower urinary tract symptoms, pain and quality of life assessment in chronic nonbacterial prostatitis patients treated with α-blocking agent doxazosin; versus placebo. Int Urol Nephrol. 2002;34:351
  29. Lu M, Zhao ST, Wang SM, Shi BK, Fan YD, Wang JZ. Alpha-blockers and bioflavonoids in men with chronic nonbacterial prostatitis (NIH-IIIa): a prospective, placebo-controlled trial. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25:169
  30. Argyropoulos A, Papadopoulos G, Liapis D, Polyzois K, Liakatas I, Fragoulis A, et al. The use of alfuzosin for the treatment of chronic prostatitis/chronic pelvic pain syndrome: is there a role for α-blockers?. Eur Urol. 2004;3(suppl):204
  31. Tripp DA, Nickel JC, Landis JR, Wang YL, Knauss JS CPCKN Study Group. Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study. BJU Int. 2004;94:1279
  32. Cheah PY, Liong ML, Yuen KH, Teh CL, Khor T, Yang JR, et al. Initial, long-term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology. 2004;64:881
  33. Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington J, et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol. 2003;169:1401

 For another article on a related topic see page 377.

PII: S0022-5347(06)02170-7

doi: 10.1016/j.juro.2006.08.090

The Journal of Urology
Volume 177, Issue 1 , Pages 25-30 , January 2007

Article Tools